Contrasting Milestone Pharmaceuticals (NASDAQ:MIST) and Ascend Wellness (OTCMKTS:AAWH)

Ascend Wellness (OTCMKTS:AAWH) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Earnings & Valuation

This table compares Ascend Wellness and Milestone Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascend Wellness	$500.58 million	0.15	-$118.19 million	($0.57)	-0.64
Milestone Pharmaceuticals	$1.55 million	53.17	-$63.06 million	($0.69)	-0.96

Milestone Pharmaceuticals has lower revenue, but higher earnings than Ascend Wellness. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascend Wellness, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ascend Wellness and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ascend Wellness	-23.31%	N/A	-10.85%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Risk & Volatility

Ascend Wellness has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Ascend Wellness and Milestone Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascend Wellness	0	1	0	0	2.00
Milestone Pharmaceuticals	1	1	4	1	2.71

Milestone Pharmaceuticals has a consensus price target of $6.40, suggesting a potential upside of 866.77%. Given Milestone Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Ascend Wellness.

Insider and Institutional Ownership

17.3% of Ascend Wellness shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 21.9% of Ascend Wellness shares are held by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Milestone Pharmaceuticals beats Ascend Wellness on 8 of the 15 factors compared between the two stocks.

About Ascend Wellness

Ascend Wellness Holdings, Inc. is a vertically integrated cannabis company that cultivates, manufactures, and sells cannabis products in the United States. The company serves both medical and adult-use markets, subject to applicable state regulations. Ascend’s product portfolio includes flower, pre-rolls, vapes, concentrates, edibles, and other cannabis products sold under brands such as Ozone, Simply Herb, Common Goods, and &Shine. The company distributes products through its own retail dispensaries and through wholesale channels serving third-party cannabis retailers.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s research is centered on treatments designed to provide rapid, patient-administered relief for episodic cardiovascular disorders. Milestone’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. The therapy has been developed primarily for the treatment of paroxysmal supraventricular tachycardia, or PSVT, a condition characterized by episodes of abnormally rapid heart rate.